NEUROTERA highlighted on Compete 2020's newsletter

NEUROTERA: Development of innovative drugs against ocular and cerebral co-morbidities associated to Familial Amyloid Polyneuropathy (TTR-FAP).

This project aims at the development of therapeutic drugs to increase survival and improve the quality of life of patients with hereditary transthyretin amyloidosis and its co-morbidities. Another goal of the project is to contribute to reducing costs with treatments supported by health services and families, through providing more effective therapies.

Read more here